Bantampharma.com Website Review

Bantam Pharmaceutical is developing first-in-clas* small molecule oncology thera*eutics for hematological cancers and select solid Bantam’s lead drug candidate is an orally available compound with a novel mechanism of action that activates the Integrated Stress Response through modulation of eIF2α and induction of the ATF4 pathway. Bantam is seeking partners and investors to facilitate rapid progression of its clinical candidate through IND filing and proof of In human tumor xenograft studies of Diffuse Large B-Cell Lymphoma, treatment (single agent, once daily dosing) with Bantam’s lead compound (BTM-3566) results in complete tumor regression, along with durable remission upon withdrawal.  Studies demonstrate that Bantam’s compounds also exhibit substantial tumor growth inhibition in solid tumors – KRAS-mutated colorectal and lung cancer. The compounds have a unique mechanism of action (MoA), distinct from currently known targeted thera*eutics, including histone deacetylase, proteasome, and kinase inhibitors. The MoA is a series of actions that lead to activation of the eIF2α – ATF4 Integrated Stress Response pathway, and culminate with cancer cell apoptosis or suppression of tumor growth.  Activation of the ATF4 pathway is specific:  the compound does not activate other cellular stress pathways including DNA Damage, ER stress, Autophagy or Oxidative Stress.  A unique set of patient selection markers have been identified that are functionally related to activation of the ATF4 ISR pathway by Bantam’s compounds offer a new thera*eutic approach that will expand the treatment options for relapsed and refractory DLBCL and difficult Bantam owns a rich intellectual property estate that includes the compounds and broad utility claims. Bantam has also filed patent applications that include claims related to the mechanism, production, indications, and routes of administration. These filings protect Bantam’s pipeline and any derivative products at least through 2038.